American Heart Journal
Volume 155, Issue 2 , Pages 208-214 , February 2008

The clinical need for high-sensitivity cardiac troponin assays for acute coronary syndromes and the role for serial testing

  • Alan H.B. Wu, PhD

      Affiliations

    • Department of Laboratory Medicine, Clinical Chemistry Laboratory, San Francisco General Hospital, University of California, San Francisco, CA
    • Corresponding Author InformationReprint requests: Alan H. B. Wu, PhD, San Francisco General Hospital, Room 2M27, 1001 Potrero Ave, San Francisco, CA 94110.
    • ,
  • Allan S. Jaffe, MD

      Affiliations

    • Cardiovascular Division and Division of Laboratory Medicine, Mayo Clinic, Rochester, MN

Received 10 August 2007 ,Accepted 12 October 2007.

References 

  1. Morrow DA, Cannon CP, Jesse RL, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation. 2007;115:e356–e375
  2. Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined—a consensus document of the joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;36:959–969
  3. Luepker RV, Apple FS, Christenson RH, et al. AHA scientific statement: case definitions for acute coronary heart disease in epidemiology and clinical research studies. Circulation. 2003;107:2543–2549
  4. Adams JE, Bodor GS, Davila-Roman VG, et al. Cardiac troponin I. A marker with high specificity for cardiac injury. Circulation. 1993;88:101–106
  5. Hamm CW, Ravkilde J, Gerhardt W, et al. The prognostic value of serum troponin T in unstable angina. N Engl J Med. 1992;327:146–150
  6. Galvani M, Ottani F, Ferrini D, et al. Prognostic influence of elevated values of cardiac troponin I in patients with unstable angina. Circulation. 1997;95:2053–2059
  7. Wu AHB, Valdes R, Apple FS, et al. Cardiac troponin-T immunoassay for diagnosis of acute myocardial infarction and detection of minor myocardial injury. Clin Chem. 1994;40:900–907
  8. Guest TM, Ramanathan AV, Tuteur PG, et al. Myocardial injury in critically ill patients. A frequently unrecognized complication. JAMA. 1995;273:1945–1949
  9. Newby LK, Storrow AB, Gibler WB, et al. Bedside multimarker testing for risk stratification in chest pain units: the chest pain evaluation by creatine kinase–MB, myoglobin, and troponin I (CHECKMATE) study. Circulation. 2001;103:1832–1837
  10. Brown AM, Sease KL, Robey JL, et al. The impact of B-type natriuretic peptide in addition to troponin I, creatine kinase–MB, and myoglobin on the risk stratification of emergency department chest pain patients with potential acute coronary syndrome. Ann Emerg Med. 2007;40:153–163
  11. Jaffe AS, Katus H. Acute coronary syndrome biomarkers. The need for more adequate reporting. Circulation. 2004;110:104–106
  12. Apple FS, Parvin CA, Christenson RH, et al. Validation of the 99th percentile cutoff for cardiac troponin monitoring for detection of myocardial infarction. Clin Chem. 2005;51:2198–2200
  13. Long GL, Winefordner JD. Limit of detection. Anal Chem. 1983;55:712A–719A
  14. International Federation of Clinical Chemistry Committee on Standardization of Markers of Cardiac Damage. http://www.ifcc.org/index.php?option=com_remository&Itemid=120&func=fileinfo&id=87.
  15. Wu AHB, Fukushima F, Puskas R, et al. Development and preliminary clinical validation of a high-sensitivity assay for cardiac troponin using a capillary flow (single molecule) fluorescence detector. Clin Chem. 2006;52:2157–2159
  16. Panteghini M, Pagani F, Yeo KTJ, et al. Evaluation of the imprecision at low-range concentration of the assays for cardiac troponin determination. Clin Chem. 2004;50:327–332
  17. Apple FS, Murakami MM. Serum 99th percentile reference cutoffs for seven cardiac troponin assays. Clin Chem. 2004;50:1477–1479
  18. Apple FS, Murakami MM. Serum and plasma cardiac troponin I 99th percentile reference values for 3 2nd-generation assays. Clin Chem. 2007;53:1558–1560
  19. Wu AHB, Lu A, Freese B, et al. Development and preliminary clinical validation of an ultra-sensitive assay for cardiac troponin using microparticle-based immunoassay and single molecule counting. Clin Chem. 2007;53(Suppl):A15;[Abstract]
  20. Bao P, Wei TF, Cork K, et al. A novel technology platform for the ultrasensitive detection of cardiac troponin (cTnI): clinical utility in the emergency department. In: 2nd Int Symposium. Integrated Biomarkers in Cardiovascular Disease. Berlin, June, 2007. 2007;[Abstract]
  21. Amodio G, Antonelli G, Varraso L, et al. Clinical impact of the troponin 99th percentile cut-off and clinical utility of myoglobin measurement in the early management of chest pain patients admitted to the emergency cardiology department. Coron Artery Dis. 2007;18:181–186
  22. Melanson SEF, Morrow DA, Jarolim P. Earlier detection of myocardial injury in a preliminary evaluation using a new troponin I assay with improved sensitivity. Am J Clin Pathol. 2007;128:282–286
  23. Eggers KM, Oldgren J, Nordenskjold A, et al. Diagnostic value of serial measurement of cardiac markers in patients with chest pain: limited value of adding myoglobin to troponin I for exclusion of myocardial infarction. Am Heart J. 2004;148:574–581
  24. Kavsak PA, MacRae AR, Newman AM, et al. Effects of contemporary troponin assay sensitivity on the utility of the early markers myoglobin and CKMB isoforms in evaluating patients with possible acute myocardial infarction. Clin Chim Acta. 2007;380:213–216
  25. MacRae AR, Kavsak PA, Lustig V, et al. Assessing the requirement for the 6-hour interval between specimens in the American Heart Association classification of myocardial infarction in epidemiology and clinical research studies. Clin Chem. 2006;52:812–818
  26. Venge P, Lagerqvist B, Diderholm E, et al. Clinical performance of three cardiac troponin assays in patients with unstable coronary artery disease (a FRISC II substudy). Am J Cardiol. 2002;89:1035–1041
  27. James SK, Lindahl B, Armstrong P, et al. A rapid troponin I assay is not optimal for determination of troponin status and prediction of subsequent cardiac events at suspicion of unstable coronary syndromes. Int J Cardiol. 2004;93:113–120
  28. Morrow DA, Cannon CP, Rifai N, et al. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA. 2001;286:2405–2412
  29. Kavsak PA, Newman AM, Lustig V, et al. Long-term health outcomes associated with detectable troponin I concentrations. Clin Chem. 2007;53:220–227
  30. Eggers KM, Lagerqvist B, Venge P, et al. Persisting troponin I elevations predict adverse outcome in stabilized patients after an episode of acute coronary syndrome. Circulation. 2006;114:II 417;[Abstract]
  31. Zethelius B, Johnston N, Venge P. Troponin I as a predictor of coronary heart disease and mortality in 70-year old men. A community-based cohort study. Circulation. 2006;113:1071–1078
  32. Schulz O, Paul-Walter C, Lehmann M, et al. Usefulness of detectable levels of troponin, below the 99th percentile of the normal range, as a clue to the presence of underlying coronary artery disease. Am J Cardiol. 2007;100:764–769
  33. Apple FS, Murakami MM, Pearce LA, et al. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation. 2002;106:2941–2945
  34. Wallace TW, Abdullah SM, Drazner MH, et al. Prevalence and determinants of troponin T elevation in the general population. Circulation. 2006;113:1958–1965
  35. Makaryus AN, Makaryus MN, Hassid B. Falsely elevated cardiac troponin I levels. Clin Cardiol. 2007;30:92–94
  36. Babuin L, Jaffe AS. Troponin: the biomarker of choice for the detection of cardiac injury. CMAJ. 2005;173:1191–1202
  37. Jeremias A, Gibson CM. Narrative review: alternative causes for elevated cardiac troponin levels when acute coronary syndromes are excluded. Ann Intern Med. 2005;142:786–791
  38. Wu AHB, Apple FS, Jaffe AS, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines: use of cardiac troponin and the natriuretic peptides for etiologies other than acute coronary syndromes and heart failure. Clin Chem. 2007;[submitted]
  39. Lamb EJ, Kenny C, Abbas NA, et al. Cardiac troponin I concentration is commonly increased in nondialysis patients with CKD: experience with a sensitive assay. Am J Kidney Dis. 2007;49:507–516
  40. Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. Circulation. 1979;59:607–609
  41. Clerico A, Zucchelli GC, Piol A, et al. Clinical relevance of biological variation of B-type natriuretic peptide. Clin Chem. 2005;51:925–926
  42. Fraser CG. Biological variation: from principles to practice. Washington (DC): AACC Press; 2001;

PII: S0002-8703(07)00830-7

doi: 10.1016/j.ahj.2007.10.016

American Heart Journal
Volume 155, Issue 2 , Pages 208-214 , February 2008

Article Tools

* Image Usage & Resolution